ShockWave Medical, Inc. (SWAV)
| Market Cap | 5.19B |
| Revenue (ttm) | 67.79M |
| Net Income (ttm) | -65.70M |
| Shares Out | 33.09M |
| EPS (ttm) | -1.99 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 6 |
| Last Price | $144.89 |
| Previous Close | $148.46 |
| Change ($) | -3.57 |
| Change (%) | -2.40% |
| Day's Open | 147.14 |
| Day's Range | 138.21 - 150.94 |
| Day's Volume | 383,673 |
| 52-Week Range | 37.76 - 169.00 |
New Technology Add-on Payment (NTAP) Included in Proposed Fiscal Year 2022 Rule New Technology Add-on Payment (NTAP) Included in Proposed Fiscal Year 2022 Rule
SANTA CLARA, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular...
SANTA CLARA, Calif., April 12, 2021 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex cal...
Which of these amazing medical technology companies is better for your portfolio for the next decade?
The company announced preliminary first-quarter results.
Announces Preliminary Revenue Range for the First Quarter of 2021 Announces Preliminary Revenue Range for the First Quarter of 2021
Buying these stocks is a smart way to make that stimulus check work for your future.
The medical-device maker needs to keep its foot on the revenue gas.
And investors have lots to like.
Hint: Focus on the business, not the stock.
Shockwave Medical (SWAV) delivered earnings and revenue surprises of -12.20% and 11.60%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of ShockWave Medical (NASDAQ:SWAV) were unchanged in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 6.12% year over year to ($0.46), wh...
SANTA CLARA, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calc...
Shockwave Medical (SWAV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Shockwave Medical to Report Fourth Quarter and Full Year 2020 Financial Results on February 17, 2021
SANTA CLARA, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calc...
No news is good news for this company.
No news was good news for the medical device maker.
With so much hype baked into the market, smart speculators may want to consider these under-the-radar breakout stocks for 2021. The post 7 Under-the-Radar Breakout Stocks for 2021 appeared first on Inve...
Four New C-Codes for IVL Performed Below the Knee in Hospital Outpatient Setting Four New C-Codes for IVL Performed Below the Knee in Hospital Outpatient Setting
Smid-cap MedTech company ShockWave Medical Inc (NASDAQ: SWAV) has seen its shares appreciate over 120% year-to-date. The ShockWave Analyst: BofA Securities analyst Bob Hopkins downgraded ShockWave from ...
SANTA CLARA, Calif., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular d...
ShockWave has key differentiators that look set to make a remedial breakthrough in peripheral vascular interventions. The CAD III and PAD III IVL studies have shown superior efficacy and safety results ...
Shockwave Medical, Inc. (SWAV) CEO Douglas Godshall on Q3 2020 Results - Earnings Call Transcript
Shockwave Medical (SWAV) delivered earnings and revenue surprises of 30.91% and 34.87%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of ShockWave Medical (NASDAQ:SWAV) were flat in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were up 17.39% year over year to ($0.38), which be...
SANTA CLARA, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calc...
Disrupt PAD III is Largest Randomized Study of Complex Patients Typically Excluded from Clinical Trials Disrupt PAD III is Largest Randomized Study of Complex Patients Typically Excluded from Clinical T...
Shockwave Medical (SWAV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SANTA CLARA, Calif., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calc...
SANTA CLARA, Calif., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat severely cal...
You won't see many headlines about these stocks. But they're well positioned to deliver big gains.
Positive Disrupt CAD III Data Submitted to FDA in Premarket Approval Application Positive Disrupt CAD III Data Submitted to FDA in Premarket Approval Application
SANTA CLARA, Calif., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat severely cal...
SANTA CLARA, Calif., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular...
ShockWave Medical's (SWAV) CEO Doug Godshall on Q2 2020 Results - Earnings Call Transcript
Shares of ShockWave Medical (NASDAQ:SWAV) moved higher by 1.5% in after-market trading after the company reported Q2 results.
Shockwave Medical (SWAV) delivered earnings and revenue surprises of 15.15% and 6.04%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
SANTA CLARA, Calif., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex ca...
Shockwave Medical (SWAV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SANTA CLARA, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular...
SANTA CLARA, Calif., July 21, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex ca...
SANTA CLARA, Calif., July 20, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular...
The company isn't taking the ruling lying down.
SANTA CLARA, Calif., July 08, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular...
Catalysts are potentially on the way for these leading medical device stocks.
SANTA CLARA, Calif., June 16, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (“Shockwave”) (Nasdaq: SWAV) today announced the pricing of its public offering of 1,700,000 shares of its common stock a...
SANTA CLARA, Calif., June 16, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (“Shockwave”) (Nasdaq: SWAV) today announced it has commenced an underwritten public offering of 1,700,000 shares of its ...
Centers for Medicare & Medicaid Services Issues New Codes for Peripheral Intravascular Lithotripsy Performed in Hospital Outpatient and Inpatient Settings Centers for Medicare & Medicaid Services Issues...
ShockWave Medical, Inc. (SWAV) CEO Doug Godshall on Q1 2020 Results - Earnings Call Transcript
Shockwave Medical (SWAV) delivered earnings and revenue surprises of -22.92% and 20.52%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
About SWAV
ShockWave Medical, Inc., a medical device company, engages in developing and commercializing intravascular lithotripsy technology to treat calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee peripheral artery disease. It serves interventional cardiologists, vascular surgeons, and interventional radiologists ... [Read more...]
| Industry Medical Devices | IPO Date Mar 7, 2019 |
| CEO Douglas Godshall | Employees 449 |
| Stock Exchange NASDAQ | Ticker Symbol SWAV |
Financial Performance
In 2020, SWAV's revenue was $67.79 million, an increase of 57.92% compared to the previous year's $42.93 million. Losses were -$65.70 million, 28.5% more than in 2019.
Analyst Forecasts
According to 6 analysts, the average rating for SWAV stock is "Buy." The 12-month stock price forecast is 151.80, which is an increase of 4.77% from the latest price.